1. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
   Jasmeet Kaur et al, 2021, Expert Opinion on Emerging Drugs CrossRef
2. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells
   Longchao Liu et al, 2021, Nature Biomedical Engineering CrossRef
3. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo
   PAN MA et al, 2015, Oncology Reports CrossRef
4. Development and clinical application of bispecific antibody in the treatment of colorectal cancer
   Maryam Balibegloo et al, 2020, Expert Review of Clinical Immunology CrossRef
5. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
   Juan Ma et al, 2016, Oncotarget CrossRef
6. Somatic mutation profiling, tumor-infiltrating leukocytes, tertiary lymphoid structures and PD-L1 protein expression in HER2-amplified colorectal cancer
   Xiao-Ting Liu et al, 2023, PeerJ CrossRef
7. Tumor-Targeted Antibodies
   Aurélien Marabelle, 2018, Oncoimmunology CrossRef
8. Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
   Hui Xiong et al, 2021, Antibody Therapeutics CrossRef
9. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer
   Huijun Zhao et al, 2019, Investigational New Drugs CrossRef
10. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
    Shengnan Yu et al, 2017, Experimental Hematology & Oncology CrossRef
11. The Evolving Landscape of HER2-Directed Breast Cancer Therapy
    Juan Luis Gomez Marti et al, 2020, Current Treatment Options in Oncology CrossRef
12. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
    Z. Wu et al, 2018, Pharmacology & Therapeutics CrossRef
13. Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody
    Wanru Ma et al, 2018, Cancer Medicine CrossRef